Oxford BioDynamics PLC Issue of Equity (9261B)
26 September 2018 - 4:00PM
UK Regulatory
TIDMOBD
RNS Number : 9261B
Oxford BioDynamics PLC
26 September 2018
OXFORD BIODYNAMICS PLC
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Issue of Equity
Oxford BioDynamics Plc (AIM: OBD) (the "Company"), a
biotechnology company focused on the discovery and development of
epigenetic biomarkers based on regulatory genome architecture for
use within the pharmaceutical and biotechnology industry, announces
that it has made an application to the London Stock Exchange for
the admission to trading on AIM of 304,832 new ordinary shares of
1p each ("New Shares") to satisfy the exercise of options granted
under the Company's share option schemes.
The New Shares are expected to be admitted to trading on AIM on
2 October 2018.
Following this admission, the Company's share capital and total
voting rights comprises 92,506,138 ordinary shares of 1p each and
the Company does not hold any shares in treasury. Consequently,
92,506,138 is the figure which may be used by shareholders as the
denominator for the calculation by which they will determine if
they are required to notify their interest in, or a change to their
interest in, securities of the Company under the FCA's Disclosure
and Transparency Rules.
-ENDS-
Oxford BioDynamics Plc. +44 (0)1865 518910
Christian Hoyer Millar, CEO
Paul Stockdale, CFO
Shore Capital +44 (0)20 7408 4090
Nominated Adviser and Broker
Stephane Auton
Edward Mansfield
FTI Consulting +44 (0)20 3727 1000
Financial Public Relations
Advisor
Brett Pollard
Natalie Garland-Collins
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOESEFFAIFASESU
(END) Dow Jones Newswires
September 26, 2018 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024